exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088155 RNA Name: hsa-miR-320b RNA Type: miRNA Chromosome: chr1 Starnd: - Coordinate: Start Site(bp): 224257049 End Site(bp): 224257070 External Links: hsa-miR-320b

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ACAP2 chr3 195274745 195443044 - ASB1 chr2 238426742 238452250 + BLCAP chr20 37492472 37527931 - BTAF1 chr10 91923770 92030325 + CGN chr1 151510510 151538692 + CKAP5 chr11 46743048 46846308 - CRTC3 chr15 90529923 90645345 + FJX1 chr11 35618460 35620865 + GNAI2 chr3 50226292 50259362 + HECTD2 chr10 91409280 91514829 + IGF2BP3 chr7 23310209 23470491 - MAPKAPK2 chr1 206684944 206734283 + NR4A2 chr2 156324437 156342348 - PFN1 chr17 4945652 4949061 - SGK1 chr6 134169246 134318112 - SIN3A chr15 75369379 75455842 - SRSF7 chr2 38743599 38751494 - TRIM14 chr9 98069275 98119222 - ZCCHC2 chr18 62523025 62587709 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000417 chr12 69644908 69656342 + hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0000095 chr1 95609446 95616975 + hsa_circ_0000744 chr17 15968183 15971435 - hsa_circ_0000652 chr15 90984737 90986710 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC002044.1 chr16 73014319 73014476 - AC016876.2 chr17 7581964 7584086 - AC092718.4 chr16 81030770 81031485 + AL022311.1 chr22 37876148 37895563 + AL162258.1 chr1 153626332 153634340 - DLEU1 chr13 50082169 50906856 + GAS5 chr1 173858559 173868882 - LINC00641 chr14 21200079 21206900 - MALAT1 chr11 65497688 65506516 + MIR3142HG chr5 160438594 160487426 + NEAT1 chr11 65422774 65445540 + NR2F2-AS1 chr15 96110040 96327361 - OIP5-AS1 chr15 41283990 41309737 + SNHG1 chr11 62851984 62855953 - SNHG12 chr1 28578538 28583132 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.